Mycobacterial hsp65 antigen upregulates the cellular immune response of healthy individuals compared with tuberculosis patients

• Autor(a) principal: Pryscilla Fanini Wowk
• Data de Publicação: 2017
• Outros Autores: Flávia Dias Coelho Silva, Solange Alves Vinhas, Olindo Assis Martins Filho, Moisés Palaci, Célio Lopes Silva, Vânia Luiza Deperon Bonato, Luís Henrique Franco, Denise Morais da Fonseca, Marina Oliveira Paula, Élcio Dos Santos Oliveira Vianna, Ana Paula Barbosa Wedling, Valéria Maria Augusto, Silvana Maria Elói Santos, Andréa Teixeira Carvalho
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFMG
• Texto Completo: http://hdl.handle.net/1843/54960
• topic: Interferon beta; Interleucina-10; Tuberculosis; Vacine; Interferon beta; Interleucina-10; Tuberculose; Vaccinia

Previously we showed that 65-kDa Mycobacterium leprae heat shock protein (Hsp65) is a target for the development of a tuberculosis vaccine. Here we evaluated peripheral blood mononuclear cells (PBMC) from healthy individuals or tuberculosis patients stimulated with two forms of Hsp65 antigen, recombinant DNA that encodes Hsp65 (DNA-HSP65) or recombinant Hsp65 protein (rHsp65) in attempting to mimic a prophylactic or therapeutic study in vitro, respectively. Proliferation and cytokine-producing CD4C or CD8C cell were assessed by flow cytometry. The CD4C cell proliferation from healthy individuals was stimulated by DNA-HSP65 and rHsp65, while CD8C cell proliferation from healthy individuals or tuberculosis patients was stimulated by rHSP65. DNA-HSP65 did not improve the frequency of IFN gammaC cells from healthy individuals or tuberculosis patients. Furthermore, we found an increase in the frequency of IL-10-producing cells in both groups. These findings show that Hsp65 antigen activates human lymphocytes and plays an immune regulatory role that should be addressed as an additional antigen for the development of antigen-combined therapies.